CA
CRSP icon

Clearstead Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Clearstead Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36K Buy
80
+5
+7% +$264 ﹤0.01% 2233
2026
Q1 		$3.57K Sell
75
-802
-91% -$42.3K ﹤0.01% 1785
2025
Q4 		$46K Sell
877
-40
-4% -$2.4K ﹤0.01% 1438
2025
Q3 		$59.4K Buy
917
+40
+5% +$2.3K ﹤0.01% 1224
2025
Q2 		$42.7K Sell
877
-166
-16% -$6.42K ﹤0.01% 1329
2025
Q1 		$35.5K Buy
1,043
+799
+327% +$33.9K ﹤0.01% 1259
2024
Q4 		$9.6K Sell
244
-619
-72% -$29.2K ﹤0.01% 1579
2024
Q3 		$40.5K Buy
863
+42
+5% +$2.13K ﹤0.01% 1249
2024
Q2 		$44.3K Hold
821
– – ﹤0.01% 1194
2024
Q1 		$45.7K Buy
821
+802
+4,221% +$57.4K ﹤0.01% 787
2023
Q4 		$1.19K Sell
19
-128
-87% -$7.08K ﹤0.01% 1382
2023
Q3 		$6.67K Buy
147
+131
+819% +$6.77K ﹤0.01% 1172
2023
Q2 		$899 Buy
+16
New +$908 ﹤0.01% 1260
2022
Q4 		– Sell
-40
Closed -$3K – 1332
2022
Q3 		$3K Hold
40
– – ﹤0.01% 1021
2022
Q2 		$2K Buy
40
+10
+33% +$588 ﹤0.01% 1099
2022
Q1 		$2K Sell
30
-264
-90% -$16.6K ﹤0.01% 1193
2021
Q4 		$22K Sell
294
-46
-14% -$4.02K ﹤0.01% 801
2021
Q3 		$38K Buy
340
+294
+639% +$36.9K ﹤0.01% 653
2021
Q2 		$7K Hold
46
– – ﹤0.01% 835
2021
Q1 		$6K Sell
46
-6
-12% -$906 ﹤0.01% 843
2020
Q4 		$8K Buy
+52
New +$6.15K ﹤0.01% 744

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's CRSP Position: Q2 2026 in Review

Clearstead Advisors increased its CRISPR Therapeutics (CRSP) stake by 6.7% in Q2 2026, buying an estimated $264 and bringing the position to 80 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #2233.

Clearstead Advisors first reported a position in CRSP in Q4 2020 and has held it in 21 quarters since. The position peaked at $59.4K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Clearstead Advisors held 80 shares of CRISPR Therapeutics worth $4.36K as of Q2 2026.
  • Clearstead Advisors bought 5 CRISPR Therapeutics shares in Q2 2026, an estimated $264.
  • CRISPR Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2233 holding.
  • Clearstead Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Clearstead Advisors's CRISPR Therapeutics position peaked at $59.4K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.